References
- al RefaieFNHershkoCHoffbrandAVResults of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron ChelatorsBr J Haematol19959122497577638
- Apotex2004 Ferriprox package insert
- Borgna-PignattiCCappelliniMDDe StefanoPCardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia majorBlood20061073733716373663
- BrittenhamGMGriffithPMNienhuisAWEfficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia majorN Engl J Med1994331567738047080
- CabantchikZIBreuerWZanninelliGLPI-labile plasma iron in iron overloadBest Pract Res Clin Haematol2005182778715737890
- CappelliniMDBejaouiMAgaogluLPatient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy [abstract]Blood20051062704
- CappelliniMDCohenAPigaAA Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalas-semiaBlood200610734556216352812
- CighettiGDucaLBortoneLOxidative status and malondialdehyde in beta-thalassaemia patientsEur J Clin Invest200232Suppl 1556011886433
- CohenAMaseraGZoumbosNEffect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade®, ICL670) [abstract]Blood2005106822
- CunninghamMJMacklinEANeufeldEJComplications of beta-thalassemia major in North AmericaBlood200410434914988152
- DaarSTaherAPathareADeferasirox (Exjade® ICL 670) provides 24-hour protection from labile plasma iron (LPI), in iron overloaded β-thalassaemia patients previously chelated with mono- or combination therapy [abstract]Haematologica200691Suppl 131
- De LucaCFilosaAGrandinettiMBlood antioxidant status and urinary levels of catecholamine metabolites in beta-thalassemiaFree Radic Res1999304536210400457
- EleftheriouPTannerMPennellDResponse of myocardial T2* to oral deferasirox monotherapy for 1 year in 29 patients with transfusion-dependent anaemias; a subgroup analysis [abstract]Haematologica200691Suppl 1999
- [EMEA] European Medicines AgencyFerriprox European Public Assessment Report, Scientific Discussion2005 www emea eu int
- [Exjade PI] Novartis Pharmaceuticals CorporationExjade (deferasirox) Prescribing information [online]2005 Accessed on 20 February 2007. URL: http://www.exjade.com
- ForniGLPigaAGalanelloRGrowth and sexual development in pediatric patients treated over 48 weeks with ICL670, a once-daily oral iron chelator [abstract]Ped Blood Cancer2005441106
- GalanelloRPigaAAlbertiDSafety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemiaJ Clin Pharmacol2003435657212817519
- GalanelloRPigaAForniGLPhase II clinical evaluation of deferasirox (Exjade, ICL670), a once-daily oral chelating agent, in paediatric patients with β-thalassaemia majorHaematologica20069113435117018383
- GattermannNCazzolaMGreenbergPThe efficacy and tolerability of ICL670, a once-daily oral iron chelator, in patients with myelodysplastic syndrome (MDS) and iron overloadLeuk Res200529Suppl 1S67
- GlicksteinHBen ElRShvartsmanMIntracellular labile iron pools as direct targets of iron chelators. A fluorescence study of chelator action in living cellsBlood200510632425016020512
- GreenbergPDineGGanserADeferasirox (Exjade®, ICL670) demonstrates dose-related effects on body iron levels related to transfusional iron intake in transfusion-dependent anemia [abstract]Blood20051062694
- GreenbergPLBaerMRBennettJMMyelodysplastic syndromes clinical practice guidelines in oncologyJ Natl Compr Canc Netw20064587716403405
- HershkoCKonijnAMNickHPICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in cultureBlood20019711152211159545
- HoffbrandAVCohenAHershkoCRole of deferiprone in chelation therapy for transfusional iron overloadBlood2003102172412637334
- IshizakaNSaitoKMitaniHIron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formationCirculation20021061840612356639
- ModellBKhanMDarlisonMSurvival in beta-thalassaemia major in the UK: data from the UK Thalassaemia RegisterLancet20003552051210885361
- NickHAcklinPLattmannRDevelopment of tridentate iron chelators: from desferrithiocin to ICL670Curr Med Chem20031010657612678677
- NickHWongAAcklinPICL670A: preclinical profileAdv Exp Med Biol200250918520312572995
- Nisbet-BrownEOlivieriNFGiardinaPJEffectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trialLancet2003361159760212747879
- OlivieriNFNathanDGMacMillanJHSurvival in medically treated patients with homozygous beta-thalassemiaN Engl J Med199433157488047081
- PennellDJBerdoukasVKaragiorgaMRandomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosisBlood200610737384416352815
- PigaAGalanelloRForniGLRandomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overloadHaematologica2006918738016818273
- PigaAGalanelloRFoschiniMLOnce-daily treatment with the oral iron chelator ICL670 (Exjade®): Results of a Phase II study in pediatric patients with β-thalassemia major [abstract]Blood20041043614
- PorterJBorgna-PignattiCBaccaraniMIron chelation efficiency of deferasirox (Exjade®, ICL670) in patients with transfusional hemosiderosis [abstract]Blood20051062690
- PorterJBAbeysingheRDMarshallLKinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapyBlood199688705138695819
- PorterJBPractical management of iron overloadBr J Haematol2001a1152395211703317
- PorterJBDeferoxamine pharmacokineticsSemin Hematol2001b3863811206963
- SteinhauserSHeinzUBartholomaMComplex formation of ICL670 and related ligands with Fe III and Fe IIEur J Inorg Chem200421417792
- TcherniaGVichinskyEJengMThe once-daily oral iron chelator ICL670 is well tolerated and effective in treating transfusional iron overload in Diamond-Blackfan anaemia patientsHaematologica200590Suppl 2192
- VichinskyEFischerRFungEA randomized, controlled Phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once-daily oral iron chelator deferasirox (Exjade®, ICL670) is well tolerated and reduces iron burden [abstract]Blood2005106313
- VichinskyEFischerRPakbazZSatisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): comparison between deferasirox (Exjade®, ICL670) and deferoxamine (DFO) [abstract]Blood2005106233415956287
- WonkeBClinical management of beta-thalassemia majorSemin Hematol200138350911605170
- WoodJCOtto-DuesselMGonzalesIICL670 removes cardiac iron in a gerbil model of iron overload [abstract]Blood20051062695